S. Sahastrabuddhe

发表

Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study

Jerome H. Kim, J. Yang, J. Lynch, 2020, EClinicalMedicine.

Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio.

R. Carbis, S. An, S. Sahastrabuddhe, 2020, Journal of pharmaceutical and biomedical analysis.

Overview of the Typhoid Conjugate Vaccine Pipeline: Current Status and Future Plans

T. Saluja, S. Sahastrabuddhe, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Euvichol story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships

Jerome H. Kim, J. Lynch, L. Digilio, 2018, Vaccine.

Enteric vaccines for resource-limited countries: current status and future prospects.

S. Desai, T. Wierzba, R. L. Ochiai, 2011, Pediatric annals.

Status of paratyphoid fever vaccine research and development.

C. MacLennan, S. Tennant, Laura B Martin, 2016, Vaccine.

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

Jerome H. Kim, J. Yang, J. Y. Park, 2022, NPJ vaccines.

Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method

S. Han, J. Yang, C. Yun, 2016, Microbial pathogenesis.

Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development

T. Wierzba, R. Carbis, S. Sahastrabuddhe, 2013, Expert review of vaccines.

Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal

Jerome H. Kim, T. Wartel, G. Rai, 2021, Human vaccines & immunotherapeutics.

Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead

Jerome H. Kim, Hanif Shaikh, J. Lynch, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus

S. Kochhar, K. Sumathy, J. Excler, 2022, Vaccine.

A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age

Min Soo Kim, Jerome H. Kim, J. Yang, 2022, The Lancet regional health. Western Pacific.

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

S. Uranw, T. Wartel, Deok-Ryun Kim, 2021, The Lancet. Infectious diseases.

Spatial and Temporal Patterns of Typhoid and Paratyphoid Fever Outbreaks: A Worldwide Review, 1990–2018

Jerome H. Kim, J. Excler, F. Marks, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine

J. Yang, J. Excler, I. Rengganis, 2019, PloS one.

A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2–11 years: a phase II preliminary report

J. Yang, S. Hadinegoro, H. I. Satari, 2020, BMC Pediatrics.

Barriers to typhoid fever vaccine access in endemic countries

B. Gessner, C. Franco-Paredes, R. L. Ochiai, 2017, Research and reports in tropical medicine.

One-month follow up of a randomized clinical trial-phase II study in 6-<24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.

J. Yang, S. Hadinegoro, H. I. Satari, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Epidemiology of Typhoid in Nepal: Review of Literature to Identify High Burden Area for Potential Use of Typhoid Vaccine

T. Saluja, S. Sahastrabuddhe, B. Gupta, 2021, Pediatric Infectious Disease.

Typhoid Fever Surveillance and Vaccine Use — South-East Asia and Western Pacific Regions, 2009–2013

E. Mintz, T. Hyde, A. Bentsi-Enchill, 2014, MMWR. Morbidity and mortality weekly report.

25 Years after Vi Typhoid Vaccine Efficacy Study, Typhoid Affects Significant Number of Population in Nepal

T. Wierzba, R. L. Ochiai, D. Bajracharya, 2014, PloS one.

Mapping the high burden areas of cholera in Nepal for potential use of oral cholera vaccine: An analysis of data from publications and routine surveillance systems

J. Lynch, T. Wartel, Chulwoo Rhee, 2020 .

Drug Resistance Patterns of Salmonellae Enterica Serotype Typhi and Paratyphi at a Tertiary Care Hospital of Sindh, Pakistan

H. Khan, S. Sahastrabuddhe, I. Memon, 2014 .

Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children

Jerome H. Kim, J. Yang, J. Lynch, 2018, Vaccine.

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

J. Yang, J. Y. Park, B. T. Tadesse, 2022, npj Vaccines.

Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate vaccines (Vi-DT vs Vi-TT)

J. Yang, M. Song, J. Y. Park, 2020, PLoS neglected tropical diseases.

Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report

Jerome H. Kim, J. Yang, J. Lynch, 2020, Vaccine.

Sexually Transmitted Infections and Risk Behaviors Among Transgender Persons (Hijras) of Pune, India

R. Bollinger, R. Gangakhedkar, S. Mehendale, 2012, Journal of acquired immune deficiency syndromes.

Formative Research and Development of an Evidence-Based Communication Strategy: The Introduction of Vi Typhoid Fever Vaccine Among School-Aged Children in Karachi, Pakistan

Z. Bhutta, I. Haq, E. Hussain, 2013, Journal of health communication.

Typhoid vaccine introduction: An evidence-based pilot implementation project in Nepal and Pakistan.

Z. Bhutta, J. Clemens, S. Soofi, 2015, Vaccine.

Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.

Jerome H. Kim, J. Yang, T. Wartel, 2022, Vaccine.

Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal

T. Wartel, G. Rai, T. Saluja, 2022, Human vaccines & immunotherapeutics.

The Need for an Information Communication and Advocacy Strategy to Guide a Research Agenda to Address Burden of Invasive Nontyphoidal Salmonella Infections in Africa.

B. Gessner, S. Sahastrabuddhe, M. Imran Khan, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Protective Effects of Influenza Vaccination in Pregnant Women on Pregnancy and Birth Outcomes in Pune, India: A Cross-Sectional Study

Hanif Shaikh, C. Upasani, S. Sahastrabuddhe, 2023, Vaccines.

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal

S. Uranw, B. Khanal, A. Ghimire, 2023, Human Vaccines & Immunotherapeutics.

Programmatic considerations for chikungunya vaccine introduction in countries at risk of chikungunya outbreaks: stakeholder analysis

S. Sahastrabuddhe, Abbas, M. Auzenbergs, 2023, medRxiv.

The Need for an Information Communication and Advocacy Strategy to Guide a Research Agenda to Address Burden of Invasive Nontyphoidal Salmonella Infections in Africa.

B. Gessner, S. Sahastrabuddhe, M. I. Khan, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Typhoid Fever Surveillance and Vaccine Use — South-East Asia and Western Pacific Regions, 2009–2013

E. Mintz, T. Hyde, A. Bentsi-Enchill, 2014, MMWR. Morbidity and mortality weekly report.

Vaccine value profile for Chikungunya

D. Beasley, S. Sahastrabuddhe, R. Hutubessy, 2023, Vaccine.